Fingolimod

For research use only. Not for therapeutic Use.

  • CAT Number: I002087
  • CAS Number: 162359-55-9
  • Molecular Formula: C19H33NO2
  • Molecular Weight: 307.5
  • Purity: ≥95%
Inquiry Now

Fingolimod(CAT: I002087), also known as FTY720, is a sphingosine 1-phosphate receptor modulator used to treat relapsing forms of multiple sclerosis (MS). It acts by binding to the sphingosine 1-phosphate receptor, preventing the egress of lymphocytes from lymphoid tissues, reducing the number of lymphocytes in circulation, and reducing their ability to attack the myelin sheaths that protect nerve fibers. Fingolimod is also being studied for potential use in other autoimmune and inflammatory disorders.


Catalog Number I002087
CAS Number 162359-55-9
Synonyms

FTY720 (free base)

Molecular Formula C19H33NO2
Purity ≥95%
Target S1P
Solubility 10 mM in DMSO
Storage -20°C
Overview of Clinical Research

<span style=”color:#000000;”><span style=”font-family:arial,helvetica,sans-serif;”><span style=”font-size:12px;”>Fingolimod is an a<span style=”font-variant-ligatures: normal; orphans: 2; widows: 2;”>poptosis stimulant and &nbsp;Immunosuppressant as well as a sphingosine 1 phosphate receptor modulator. It has been granted the orphan drug status in r</span><span style=”font-variant-ligatures: normal; orphans: 2; widows: 2;”>enal transplant rejection and multiple sclerosis.</span></span></span></span>

IUPAC Name 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
InChI InChI=1S/C19H33NO2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22/h9-12,21-22H,2-8,13-16,20H2,1H3
InChIKey KKGQTZUTZRNORY-UHFFFAOYSA-N
SMILES CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N
Reference

<p style=”/line-height:25px/”>
<br />
[1]. Rolin J, et al. FTY720 and SEW2871 reverse the inhibitory effect of S1P on natural killer cell mediated lysis of K562 tumor cells and dendritic cells but not on cytokine release. Cancer Immunol Immunother. 2010, 59(4), 575-586.<br />
[2]. Liu Y, et al. The sphingosine-1-phosphate receptor agonist FTY720 and its phosphorylated form affect the function of CD4+CD25+ T cells in vitro. Int J Mol Med. 2012, 30(1), 211-219.<br />
[3]. Wallington-Beddoe CT, et al. Disparate in vivo efficacy of FTY720 in xenograft models of Philadelphia positive and negative B-lineage acute lymphoblastic leukemia. PLoS One. 2012, 7(5), e36429.</p>

Request a Quote